Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. reports developments as a healthcare information technology company advancing electrocardiography through artificial intelligence. The company’s MyoVista Insights platform is a cloud-native, device-agnostic ECG management system designed for workflow efficiency, EHR interoperability and deployment of cleared AI-ECG algorithms in clinical workflows.
Recurring updates include commercialization of MyoVista Insights, customer and reference-site agreements with hospitals, health networks and academic programs, interoperability milestones such as Epic Toolbox designation, financial results and shareholder meeting matters. HeartSciences also discusses its MyoVista wavECG device, which is designed to provide conventional ECG functionality while supporting on-device AI-enabled solutions.
Heart Test Laboratories, Inc. (NASDAQ: HSCS) announced its initial public offering, pricing 1,500,000 units at $4.25 each, aiming for gross proceeds of approximately $6.375 million. The offering includes common stock and warrants, with each warrant allowing the purchase of one share at the same price, exercisable for five years. The offering is set to close on June 17, 2022, pending customary conditions. Funds will primarily support FDA clearance for the MyoVista device and general corporate needs. The company has received Nasdaq approval for trading under HSCS and for warrants under HSCSW.